In bladder cancer, breast cancer, and colon cancer, higher IGF2BP1/2/3 expression was observed in immunotherapy responders compared to non-responders, while the opposite trend was observed in melanoma. This evidence concerns the gene IGF2BP1 and malignant colon neoplasm.